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Abstract
BACKGROUND: Technetium Tc99m Exametazime (99mTc-HMPAO) is currently used as a radiopharmaceutical for determining 
regional cerebral blood flow and for the labelling of autologous leucocytes for infection and inflammation imaging. The HMPAO 
ligand exists in two diastereomeric forms: d,l and meso. Usually, the substance is obtained in low chemical yield in a time 
consuming procedure. Furthermore, the final product still contains some amounts of the meso-form. The aim of this study was 
to develop the efficient, reliable and fast method for isolation of the d,l-HMPAO, which would provide the ligand with high purity 
and free from the meso-diastereomer.
MATERIAL AND METHODS: The mixture of the meso- and d,l-HMPAO was synthesized in two-steps by condensation of pro-
panediamine with keto-oxime and the reduction of the obtained bisimine. The d- and l-enantiomers were separated individually 
directly from this mixture by repeated crystallizations from ethanol as their tartrate salts and pooled together in equal propor-
tions. That substance was characterized for its identity and isomeric purity using IR, HPLC and GC methods. The meso-free 
d,l-HMPAO was used for the preparation of the radiopharmaceutical freeze-dried kit for technetium-99m radiolabelling. Quality 
assessment of obtained 99mTc-d,l-HMPAO complex was performed according to the current Ph.Eur. monograph 1925 and USP 
monograph — Technetium Tc99m Exametazime Injection. To verify its biological activity, the kit-prepared 99mTc-d,l-HMPAO has 
been used for the white blood cell (WBC) labelling.
RESULTS: According to the proposed synthesis route the d,l-HMPAO was obtained with around 18–20% yield in the total time 
of 10 days. The ligand identity was confirmed and the HPLC analysis revealed more than 99% chemical purity. The undesired 
meso-form was not detected. Freeze dried kit formulation for 99mTc-labelling of d,l-HMPAO has been established and four batches 
of kits were manufactured. The radiochemical purity of 99mTc-d,l-HMPAO complex was high (> 95% of lipophilic technetium-99m 
exametazime). Brain uptake in rats reached 2.1 ± 0.3%. The in vitro labelling of WBC resulted in 68.3 ± 6.6% yield. 
CONCLUSION: A new synthesis method of d,l-HMPAO, drug substance for technetium-99m exametazime preparation has 
been developed. 
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Background
Technetium-99m exametazime (99mTc-HMPAO) has been in-
troduced as a tracer for brain imaging studies in humans as early 
as 1985 [1, 2] and its diagnostic utility has been very well docu-
mented [3, 4]. Currently, it is recommended by the European Asso-
ciation of Nuclear Medicine (EANM) for brain perfusion studies using 
Single Photon Emission Computed Tomography (SPECT) [5]. It 
is used to diagnose abnormalities in the regional cerebral blood flow 
such as those occurring after a stroke and other cerebrovascular 
diseases including epilepsy, Alzheimers disease and other forms of 
dementia, transient ischemic attacks, migraine and brain tumors. 
Another application is the labelling of autologous leucocytes for 
infection and inflammation imaging [6]. 
The synthesis of the active substance, ligand HMPAO (hexa- 
methylpropylene amineoxime) has been first described by Novotnik 
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et al. [1, 7]. As elucidated by Neirinckx et al. [3], HMPAO has two 
chiral centers producing the meso- (R,S), d- (R,R) and l- (S,S) 
diastereomers (Fig. 1).
It was originally confirmed that technetium-99m complexes of 
these two HMPAO diastereomers (meso- and d,l racemate) showed 
different properties in vivo both in rats [3, 4] and in humans [8]. 
They rapidly and easily diffused across the blood-brain barrier 
(BBB) at normal flow rates and had similar brain uptake. However, 
the d,l-complex revealed superior brain uptake and retention (4.1% 
after 8h post injection) compared to the complexes generated 
from meso-isomer (1.7%) and stereoisomeric mixtures (1.9%) [8]. 
Thus, the meso-diastereomer component decreased the radio- 
pharmaceutical concentration in the brain. In addition, the later 
studies indicated that brain uptake of 99mTc-complexes formed from 
separated d- and l-enantiomers differed. The cerebral uptake of 
99mTc-l-HMPAO and 99mTc-d,l-HMPAO complexes was similar but 
notably it was higher (1.5 fold) than for the isolated 99mTc-d-HMPAO 
complex [9, 10]. For these reasons, to reach the optimum brain up-
take, the HMPAO active substance should preferably be composed 
of d- and l-enantiomers without contribution of the meso-form. 
Consequently, the 99mTc-meso-HMPAO is specified as radiochemical 
impurity in the Technetium Tc99m Exametazime Injection mono-
graph, and its content should not be more than 5% in the final 
preparation used for investigations in humans [11, 12]. Hence, 
purity of HMPAO used as active substance for manufacturing of 
dry kits for radiopharmaceutical preparation is a critical parameter. 
The previously reported procedures of d,l-HMPAO purifica-
tion from the meso-form involved the repeated fractional crys-
tallizations of crude HMPAO from organic solvents [7, 13, 14]. 
This method is very time consuming and affords many fractions of 
varying crystallinity and diastereomeric composition. Hence, it 
results in the drastic reduction of the synthesis yield (overall yield 
reported was around 1.2 %) and the final d,l-HMPAO fraction still 
contains small (3–5%) amounts of the meso-form [13, 14].
The aim of this study was to develop the efficient, reliable 
and fast method for isolation of d,l-HMPAO, which would provide 
product with the high purity and which would be free from unde-
sired meso-diastereomer. Herein, we report the new purification 
procedure. The protocol was based on the individual separation of 
d- and l-enantiomers by crystallization of their tartrate salts directly 
from the meso,d,l-mixture. The method has been optimized against 
the in-house prepared standard substances (Chemical Reference 
Standards, CRS of each d,l-, meso-, d- and l-isomers). The puri-
fied d- and l-isomers were than pooled together to form the active 
pharmaceutical ingredient suitable for pharmaceutical kit develop-
ment. The quality of such obtained active substance synthesized 
in our laboratory was then confirmed in vitro by 99mTc labelling of 
leucocytes and in vivo by the biodistribution studies using the kit 
prepared complex of 99mTc-d,l-HMPAO.
Material and methods
Chemicals and analytical methods
All reagents and solvents used in reactions were of commercial 
quality and purchased from Sigma-Aldrich Co. (USA) and POCH 
(Poland). 1H NMR spectra were recorded using a Bruker 500 MHz 
spectrometer. CH3OD was used as solvent, and chemical shifts (d) 
were reported in ppm relative to TMS as an internal standard. 
IR spectra were recorded using Nicole iS10-Thermo Scientific 
spectrometer. Mass spectra were obtained on API 365PESciex 
turboionspray tandem mass spectrometer (ESI method). Melting 
point was determined using OptiMelt (SRS) apparatus. Analytical 
HPLC were run in a system comprising Shimadzu LC-20AD pump, 
SPD-M20A diode array detector and CBM-20A controller. Content 
of residual solvents was measured using GC system (GC 2010, 
Shimadzu) comprising a flame ionization detector (FID), a split/split-
less injection unit and a headspace HS40 (Perkin Elmer). 
Synthesis of d,l-HMPAO racemate
The d,l-HMPAO was synthesized according to published 
procedures [3, 7, 14] with minor modifications. The synthetic 
route is shown in Figure 2. Briefly, this two-step synthesis involved 
condensation of propanediamine (compound 2) with two molecular 
equivalents of the keto-oxime (compound 1) in the first step, fol-
lowed by the reduction of the obtained bisimine (compound 3) with 
sodium borohydride. These reactions yielded HMPAO (compound 4) 
as a mixture of meso- and d,l-diastereomers.
In the next steps the stereoisomers were separated using 
chemical methods as presented in Figure 3. The d- and l-enan-
tiomers were separated individually directly from the mixture of 
meso-, d- and l-HMPAO by repeated crystallizations from ethanol 
as their (–) tartrate and (+) tartrate salts respectively [7, 15]. 
The tartrate salts were converted into the free base form by 
treating the aqueous solutions of the ligand with excess of solid 
sodium carbonate followed by the extraction and crystallization 
from acetonitrile.
Figure 1. Diastereomers of HMPAO [3]
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Characterization of d,l-HMPAO as active substance
The quality testing methods of d,l-HMPAO active substance 
were standardized against Chemical Reference Standard of each 
d,l-, meso-, d- and l-isomers. The in-house prepared CRSs were 
characterized in detail in accordance with the relevant guide-
lines of European Pharmacopoeia [16]. Table 1 presents the sum-
mary of data for each CRS prepared. The identity of these com-
pounds was confirmed using the following methods: IR, 1HNMR, 
melting point and optical rotation. 
The identity of d,l-HMPAO active substance was confirmed by 
the IR spectroscopy, melting point measurement and comparison 
of the retention time with the retention time of d,l-HMPAO CRS. The 
purity was determined by the analytical HPLC method (assay and 
organic impurities) and by the GC method (residual solvents). The 
stereochemical purity of the separated diastereomers was deter-
mined using the analytical chiral HPLC column (Chiralpak AD, Daicel 
Chemical Industries LTD) and hexane/ethanol/n-butylamine mixture 
(85/15/0.05%) as the mobile phase. The flow rate of 1.2 mL/min 
and UV detection at 220 nm were used. For analysis of residual 
solvents (diethyl ether, acetonitrile and ethanol) the DB-624 column 
(Agilent) was used.
Freeze dried kit development and radiolabelling
The meso-free d,l-HMPAO was used as an active substance 
for the preparation of the radiopharmaceutical freeze-dried kit for 
technetium-99m radiolabelling. The amount of active substance 
in the single kit vial was 0.5 mg, similar to the commercially avail-
able formulation [17]. The influence of stannous chloride dihydrate 
amount on the kit performance was investigated in the range from 
0.003 mg to 0.007 mg. Freeze-drying was carried out in Christ Alpha 
1–4 LSC freeze dryer. The assay of tin(II) as SnCl2 x 2H2O in the final 
kit formulation was determined using ICP-OES OPTIMA 7300 DV 
spectrometer. Water content in the kits after lyophilization was de-
termined by Karl Fischer method using coulometric titration with 
thermal extraction (852 Titrando, Methrom AG). For radiolabelling 
the content of the freeze-dried kit was dissolved in around 4.5 mL 
of 0.9% NaCl immediately followed by addition of around 0.5 mL 
of eluate of sodium pertechnetate, 99mTcO4
− with the radioactivity 
Figure 3. Flow-chart of the d,l-HMPAO purification process
Figure 2. Synthesis route of HMPAO [3]
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of 740-925 MBq (20–25 mCi). Then the content was gently swirled 
at ambient temperature for 5 min. 
Quality assessment of the 99m Tc-d,l-HMPAO 
complex
The tests for identity, radiochemical purity and pH of 
99mTc-d,l-HMPAO were performed according to Ph.Eur. monograph 
1925 [11]. 
Biodistribution of 99m Tc-d,l-HMPAO 
Biodistribution was evaluated in Wistar rats (male, weight 
130–190 g) according to USP monograph [12]. The animal experi-
ments were approved by The 4th Local Animal Ethics Committee 
in Warsaw (authorization number 78/2011) and carried out in ac-
cordance with the principles of good laboratory practice (GLP). 
In a single experiment 3 rats were injected (tail vein) with around 
18.5–30 MBq of 99mTc-d,l-HMPAO in 100 µL, each. Animals were 
euthanized by overdose of isoflurane at five to ten minutes after 
the injection (p.i.). Samples of brain, liver and intestines (includ-
ing gall bladder) were collected, weighed and their radioactivity 
was measured in the NaI gamma counter supplied with adapter 
for the whole body measurement. The organ uptake values were 
expressed as the percent of injected dose per organ (%ID). 
White blood cell (WBC) labelling with 99mTc-d,l-
HMPAO
The radiolabelling of WBC was performed according to the 
EANM guidelines for labelling of leucocytes with 99mTc-d,l-HMPAO [6]. 
The samples of fresh blood were collected from healthy volun- 
teers. A 60-mL syringe was filled with 9 mL of acid citrate-dextrose 
anticoagulant (ACD, Sigma-Aldrich Co., USA) solution and 51 mL 
of the volunteers blood. Then the syringe with the blood–ACD solu-
tion was gently rotated. Next, the 15 mL of the blood–ACD solution 
was transferred into a Falcon centrifugation tube and centrifuged at 
2,000g at room temperature for 10 min. The cell-free plasma (CFP) 
was separated from the pellet and removed. Erythrocytes were al-
lowed to sediment with the aid of 2-hydroxyethyl starch (10% HES, 
pharmaceutical grade, Sigma-Aldrich Co., USA) and leucocyte-rich 
plasma (LRP) from blood was collected. The obtained LRP was gen-
tly resuspended with PBS and centrifuged twice at 150 g for 10 min. 
After that the supernatant from the leucocyte pellet was removed 
and the pellet was gently resuspended in 1 mL of fresh PBS and 
used for labelling. A 1 mL of freshly prepared 99mTc-HMPAO (ap-
proximately 750–1.000 MBq) in saline solution was added to the 
mixed leucocyte cell suspension and incubated for 10 min at room 
temperature with gently swirling to prevent sedimentation of the 
cells. After the incubation was completed, at least 3 mL of PBS 
were added and centrifuged at 150 g for 5 min. The supernatant 
containing unbound 99mTc-HMPAO was removed, the radioactivity 
of the pellet and the supernatant was measured to calculate the 
LE. The experiment was performed in triplicate. The labelling ef-
ficiency (LE) was calculated as LE (%) = radioactivity in the pellet / 
(radioactivity in the pellet + radioactivity in the supernatant) ´  100%. 
Results
Using the synthetic route presented in this study, the in-
termediate bisimine product (compound 3) was obtained with 
50% yield, and then reduced into a diastereomeric mixture 
(compound 4) with 37% yield. The individual d- and l-enanti-
omers were separated directly from the crude meso,d,l-HMPAO 
mixture (containing 40–50% meso-HMPAO) by techniques in-
volving the use of optically pure D-(-)- and L-(+)-tartaric acid 
as resolving agent [7, 15]. The obtained d-HMPAO D-(-)-tartrate 
and l-HMPAO L-(+)-tartrate salts were purified by repeated 
crystallization and converted into free base to give pure 
d- and l-HMPAO, without contribution of meso-isomer. The final 
mixture of d,l-HMPAO was obtained with around 18–20% yield 
from equal portions of d- and l-enantiomers in the total time of 
10 days. The identity of d,l-HMPAO was confirmed by melting 
point, IR, HPLC and GC analysis. The very sensitive and selec-
tive analytical HPLC method, demonstrated chemical purity 
of d,l-HMPAO of more than 99% (Figure 4). The content of 
undesired meso-form in the final drug substance was less than 
0.1% (limit of detection). The residual solvents were detected 
at the level of 600 ppm for ethanol, of 100 ppm for acetonitrile 
and 10 ppm for diethyl ether, which were well below acceptance 
limits stated by Ph. Eur. of 5000 ppm for ethanol and diethyl 
ether and 410 ppm for acetonitrile.
The influence of stannous chloride dihydrate content on the qua- 
lity of 99mTc-d,l-HMPAO was investigated in the series of batches of 
kits freeze-dried with various amounts of SnCl2 ´ 2H2O (0.003, 
0.005 and 0.007 mg). The radiochemical purity and biodistribution 
results were dependent on the content of stannous chloride dihydrate 
in the kit formulation. In particular, the increase of SnCl2 ´  2H2O from 
0.003 to 0.007 mg in the kit resulted in decreasing radiochemical 
purity and in lower brain uptake, as presented in Table 2.
The optimum chemical composition of the kit appeared to 
be as follows: 0.5 mg of d,l-HMPAO; 4.5 mg of sodium chloride, 
0.003 mg of stannous chloride dihydrate, freeze-dried and sealed 
under nitrogen as an inert atmosphere. 
Four batches of kits were manufactured according to that formu-
lation and tested for their quality. The summary of results is presented 
in Table 3, each value is the average result of tests performed inde-
pendently in 4 manufactured batches (standard deviations reflect 
the inter-batch variability). The impurities denoted as B, D and E 
Table 1. Characteristics of Chemical References Substances (CRS) d-HMPAO, l-HMPAO, d,l-HMPAO and meso-HMPAO.
 
Characteristic d-HMPAO l-HMPAO meso-HMPAO d,l-HMPAO
Purity (HPLC) (%) ≥ 99.0 ≥ 99.0 ≥ 91.5 ≥ 99.0
Content of meso-HMPAO (HPLC) (%) ≤ 1.0 ≤ 1.0 - ≤ 1.0
Assay (HPLC, GC and elemental analysis) (%) ≥ 97.0 ≥ 97.0 ≥ 90.0 ≥ 97.0
Compound
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are: 99mTc in colloidal form, non-lipophilic 99mTc-HMPAO complex and 
meso-isomer of non-lipophilic 99mTc-HMPAO complex, respectively, 
in accordance with the Ph.Eur. monograph 1925. 
The identity of 99mTc-d,l-HMPAO complex was confirmed by 
HPLC test (Figure 5). The radiochemical purity of 99mTc-d,l-HMPAO 
complexes obtained from the prepared kits was high (> 95% of 
lipophilic technetium-99m exametazime). The impurity A (isomer 
meso of lipophilic technetium-99m exametazime) was not detected 
and the contents of the other impurities (B + D + E) were well below 
the acceptance limit of 10%.
In all 4 tested batches the high brain uptake (about 2%) at 
15 min p.i. was observed. Liver and intestine uptake was about 
8 and 13%, respectively. The WBC labelling with the kit obtained 
99mTc-d,l-HMPAO resulted in 68.3 ± 6.6% (n = 3) yield. 
Figure 4. Comparative chromatograms of HMPAO diastereomers: (A) l-HMPAO, (B) d-HMPAO, (C) d,l-HMPAO, (D) meso-HMPAO
Table 2. The influence of SnCl2 x 2H2O content on the performance of frieze-dried kits (n = 3)
Test Requirements Amount of SnCl2 x 2H2O
0.003 mg 0.005 mg 0.007 mg
Radiochemical purity: Ph. Eur. 1925 
— [99mTc ] pertechnetate ion (C) ≤ 10% 5.1 ± 3.7% 2.2 ± 0.1% 0.7 ± 0.3%
— impurities B+D+E ≤ 10% 8.4 ± 1.9% 19.3 ± 1.2% 67.9 ± 0.8%
— isomer meso of lipophilic technetium-99m     
     exametazime (A)
≤ 5% 0.0 ± 0% 0.0 ± 0% 0.0 ± 0%
— lipophilic technetium-99m exametazime  
     and its isomer meso
≥ 80% 86.5 ± 4.2% 78.5 ± 4.9% 31.4 ± 0.6%
Biological distribution: USP 
— brain ≥ 1.5% ΙD 1.9 ± 0.0% 1.4 ± 0.3% 1.0 ± 0.2%
— liver ≤ 15% ID 9.0 ± 1.9% 9.6 ± 0.3% 34.6 ± 1,4%
— intestine ≤ 20% ID 14.6 ± 3.5% 12.4 ± 1.1% 8.8 ± 0.5%
Water content ≤ 1.0% 0.6 ± 0.1% 2.0 ± 0.1% 2.4 ± 0.2%
Table 3. Quality control results of frieze-dried kits (n = 4)
Test Requirements Results
Radiochemical purity: Ph. Eur. 1925 
— [99mTc ] pertechnetate ion (C) ≤ 10% 1.0 ± 0.7%
— impurities B+D+E ≤ 10% 3.8 ± 1.9%
— isomer meso of lipophilic technetium-99m exametazime (A) ≤ 5% 0.0 ± 0
— lipophilic technetium-99m exametazime and its isomer meso ≥ 80% 95.2 ± 1.8% 
Biological distribution:  USP
— brain ≥ 1.5% ID 2.1 ± 0.3%
— liver ≤ 15% ID 8.5 ± 0.6%
— intestine ≤ 20% ID 12.7 ± 1.7%
Water content ≤ 1.0% 0.7 ± 0.1%
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Discussion
Using a novel purification method, the active substance 
of d,l-HMPAO was prepared with high yield of around 18–20% 
in the total time of 10 days and with purity higher than 99%. 
This substance was also free from the meso diastereomer. The 
procedures described in literature so far enable the separa-
tion of d,l- and meso-HMPAO. However, due to the formation 
of amorphous phase during the crystallization from organic 
solvents the overall yield of the desired diastereomer is drasti-
cally reduced, giving an overall yield of about 1.2% [13, 14]. 
Bearing that in mind, the method proposed in this report ap-
pears superior with the one order of magnitude higher yield. 
The “classical” method is also very time consuming (total 
purification time can be up to one month) and it is difficult to 
reproduce and validate. Moreover, the d,l-fractions still con-
tains significant amounts (about 3–5%) of the meso-form [13], 
which is not the case in our development. The advantage of 
the method described herein is a more reliable separation of 
pure d,l-HMPAO. Using the optically active tartaric acids we 
have achieved very selective and simple resolving of pure 
d- and l-enantiomers. Furthermore, the repeated crystallization of 
the individual tartrate salts from ethanol led to the practically 
complete removal of meso-isomer. 
The value of the new synthesis route, leading to the active 
substance for 99mTc-d,l-HMPAO, has been clearly demonstrated 
in in vitro and in vivo studies. It is well known that the primary 
lipophilic complex of 99mTc-d,l-HMPAO is very rapidly converted 
to the secondary hydrophilic complex in the presence of plasma 
[3]. Factors which have an influence on the decomposition of the 
lipophilic complex are as follows: ionizing radiation, quantity of the 
Sn (II) ions and pH. Similarly to the commercially available kits, 
the 99mTc-d,l-HMPAO complex obtained from our kit formulation 
was stable up to 30 minutes after preparation [17]. We have also 
confirmed that the stability over time of 99mTc-exametazime prepa-
ration may be significantly extended by the addition of a freshly 
prepared stabilizing mixture of methylene blue solution [18] (the 
results are not shown). 
According to USP monograph, the required uptake of 
99mTc-d,l-HMPAO in the brain should not be less than 1.5% ID, not 
more than 20% ID in the intestines, and not more than 15% ID in 
the liver [12]. In our study the primary complex of 99mTc-d,l-HMPAO 
exhibited 2.1%ID brain uptake at 10 min p.i., which is well over 
the required limit, both the liver and intestine uptake were also 
within the required limits. When the kit obtained 99mTc-d,l-HMPAO 
was used for the radiolabelling of WBC, the labelling yields of 
68.3 ± 6.6% (n = 3) were reached, which is in accordance with 
the recommendations where radiolabelling efficiency between 
40% and 80% is expected [6]. Despite the promising in vitro and 
in vivo results the diagnostic utility of 99mTc-d,l-HMPAO containing 
the active substance synthetized by a modified purification route 
still needs to be confirmed in the clinical evaluation of brain perfu-
sion abnormalities. 
Conclusion
In this study, the new and efficient procedure for preparation of 
HMPAO ligand (hexamethylpropylene amineoxime) rich in d- and 
l-enantiomers and free from the meso-form has been reported. 
The freeze-dried kit formulated from such obtained ligand used 
as an active substance resulted in the reproducible preparation 
of drug product Technetium Tc99m Exametazime Injection of high 
radiochemical purity, favorable brain uptake in rodents and the high 
in vitro labelling yield of WBC. 
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